|
|
 |
|
| News Release |
|
|
Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. |
| 2008 Release |
|
| December 15, 2008 |
|
FDA Approves Sedative-Hypnotic Agent LUSEDRA™ Injection
|
|
| November 17, 2008 |
|
FDA Approves BANZEL™ (rufinamide) as Adjunctive Treatment for Lennox-Gastaut Syndrome
|
|
| November 11, 2008 |
|
Eisai Completes Alliance Agreement with TorreyPines Therapeutics for Genetic Research Programs to Discover Genes Associated with LOAD
-New Agreement Signed for Eisai to Purchase Research Assets-
|
|
| October 29, 2008 |
|
HOUSE OF LORDS REFUSES TO HEAR NICE'S APPEAL
|
|
| October 16, 2008 |
|
FDA Grants Full Approval to ONTAK® (denileukin diftitox) For Use in Patients with Cutaneous T-Cell Lymphoma (CTCL)
|
|
| October 8, 2008 |
|
Eisai Introduces “Chocola BB® Drink bit”, New Pharmaceutical Drink for Acne and Skin Care
|
|
| September 3, 2008 |
|
Eisai Introduces “Hotmin®” for Improving Peripheral Blood Circulation
|
|
| August 24, 2008 |
|
FDA Approves ALOXI® (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
|
|
| August 18, 2008 |
|
SymBio Pharmaceuticals and Eisai Sign License Agreement for bendamustine hydrochloride (SyB L-0501)
|
|
| July 31, 2008 |
|
Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders
|
|
| July 30, 2008 |
|
Eisai China Inc. Signs License Agreement in China for  -Lipon 300 STADA® for Diabetic Neuropathic Pain
|
|
| July 26, 2008 |
|
Eisai Receives Action Letter on Fospropofol Disodium Injection for Sedation in Diagnostic or Therapeutic Procedures -FDA's Not Approvable Letter Outlines Pathway to Potential Approval-
|
|
| July 22, 2008 |
|
U.S. FEDERAL CIRCUIT COURT OF APPEALS FULLY UPHOLDS EISAI'S FAVORABLE RULING IN ACIPHEX® PATENT INFRINGEMENT LAWSUIT AGAINST TEVA PHARMACEUTICALS AND DR. REDDY'S LABORATORIES
|
|
| July 16, 2008 |
|
Antiosteoporotic drugs “Actonel® 17.5 mg tablets” and “Benet® 17.5 mg tablets” received approval for additional indication in patients with Paget's disease of bone: Both come in new packages.
|
|
| July 9, 2008 |
|
ALOXI® (PALONOSETRON HCL) INJECTION AVAILABLE FOR PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
|
|
| July 7, 2008 |
|
Notice on Determination of Details of Stock Options (Stock Acquisition Rights) to be Allocated
|
|
| July 1, 2008 |
|
EISAI PROVIDES PRELIMINARY EFFICACY UPDATE ON EORTC PHASE III TRIAL OF DACOGEN® VERSUS SUPPORTIVE CARE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
|
|
| July 1, 2008 |
|
Proton Pump Inhibitor ACIPHEX® 20 mg Receives Approval for Short-Term Treatment of GERD in Adolescents in United States
|
|
| June 20, 2008 |
|
Notice on Allocation of Stock Options (Stock Acquisition Rights)
|
|
| June 19, 2008 |
|
Transfer of Subsidiary Stock
|
|
| June 17, 2008 |
|
HUMIRA® Subcutaneous Injection 40mg Syringe 0.8mL Now Available for the Treatment of Rheumatoid Arthritis
|
|
| May 29, 2008 |
|
Notification with Respect to Issuance of Unsecured Straight Bonds
|
|
| May 29, 2008 |
|
Termination of marketing alliance of Breathe Right® nasal strips
|
|
| May 22, 2008 |
|
NON-IONIC CONTRAST AGENTS, IOMERON® 350 AND IOMERON® 350 SYRINGE, RECEIVE APPROVAL FOR USE IN DYNAMIC CT LIVER IMAGING
|
|
| May 16, 2008 |
|
E7389 Demonstrated Anti-tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
|
|
| May 16, 2008 |
|
Eisai Presents 16 Papers Accepted for ASCO Annual Meeting Reporting the Latest Results from its Oncology Research
|
|
| May 14, 2008 |
|
Notice on New Stock Issuance in the Form of Stock Options
|
|
| May 12, 2008 |
|
Distribution of Ethical Drugs Bufferin 81mg Tablets & Bufferin 330mg Tablets
|
|
| May 9, 2008 |
|
COURT OF APPEAL MAKES DECISION FOLLOWING RULING THAT NICE PROCESS ON ANTI-DEMENTIA MEDICINES UNFAIR
|
|
| May 8, 2008 |
|
FDA ADVISORY COMMITTEE VOTES IN FAVOR OF APPROVAL OF FOSPROPOFOL DISODIUM INJECTION FOR SEDATION
|
|
| May 7, 2008 |
|
Eisai Establishes a New Subsidiary in China for Marketing Support and Maintenance of Pharmaceutical Manufacturing Machinery
|
|
| May 1, 2008 |
|
Eisai Gained Favourable Ruling by Court of Appeal, as NICE Process for Developing Guidance on Anti-dementia Medicines Ruled Unfair
|
|
| April 24, 2008 |
|
Eisai Introduces “Chocola BB® Royal 2” Vitamin B2 Drink for Extreme Fatigue A New Drink with Amino Acids and Reduced Calories
|
|
| April 21, 2008 |
|
Notice of Revised Business Forecast for Fiscal Year Ended March 31, 2008, as a Result of Acquisition of MGI PHARMA, INC.
|
|
| April 16, 2008 |
|
European Regulatory Agency Grants Orphan Status to Morphotek®'s FARLETUZUMAB (MORAb-003) and MORAb-009
|
|
| April 16, 2008 |
|
HUMIRA® received approval for the treatment of rheumatoid arthritis in Japan
|
|
| April 11, 2008 |
|
Status of the E2007 (perampanel) Development Program- Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications -
|
|
| April 3, 2008 |
|
Eisai to Resume Clinical Study to Evaluate E2012 as a Potential Next Generation Alzheimer's Disease Treatment
|
|
| March 29, 2008 |
|
Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept® Patent Infringement Lawsuit against Teva Pharmaceuticals
|
|
| March 28, 2008 |
|
Notice Concerning Shelf Registration for Issuance of Stock Options
|
|
| March 28, 2008 |
|
Notice Concerning Shelf Registration for Issuance of Straight Bonds
|
|
| March 14, 2008 |
|
Eisai Submits Application for Aricept® Oral Jelly Formulation in Japan
|
|
| March 13, 2008 |
|
Eisai and Sanko Junyaku introduce New KL-6 Test Kits for LUMIPULS® Systems for Detecting Marker of Interstitial Pneumonia
|
|
| March 12, 2008 |
|
M’s Science and Eisai Sign Option Agreement for Sigma Agonist SA4503
|
|
| March 3, 2008 |
|
FDA APPROVES ALOXI® (PALONOSETRON HCL) INJECTION FOR PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
|
|
| March 3, 2008 |
|
Vasolan® (Ischaemic Heart Disease Treatment) Received Approval for Atrial Fibrillation/Flutter and Paroxysmal Supraventricular Tachycardia
|
|
| March 1, 2008 |
|
FDA Grants Priority Review for ACIPHEX® sNDA for Short-Term Treatment of GERD in Adolescents
|
|
| February 28, 2008 |
|
Eisai Launches New CHOCOLA BB Product Lines CHOCOLA® BB Lucent C and CHOCOLA® BB Lucent Cream for Blemishes and Brown Spots on Skin
|
|
| February 13, 2008 |
|
Eisai and Accenture launch Clinical Data Management in India under global outsourcing agreement
|
|
| February 1, 2008 |
|
Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
|
|
| February 1, 2008 |
|
Eisai Decides Additional Study for Pariet® for New Indication of Non-Erosive Gastro-Esophageal Reflux Disease in Japan
|
|
| January 29, 2008 |
|
Abbott and Eisai Finalize License Agreement in Japan for Additional Indications for Adalimumab, The Only Fully Human Monoclonal anti-TNF- Antibody
|
|
| January 29, 2008 |
|
EISAI COMPLETES ACQUISITION OF MGI PHARMA
|
|
| January 28, 2008 |
|
Abbott and Eisai Announce Changes in the Sales Scheme in Japan for Adalimumab, A Fully Human Monoclonal Anti-TNF- Antibody
|
|
| January 23, 2008 |
|
EISAI ANNOUNCES SATISFACTION OF CONDITIONS TO TENDER OFFER FOR MGI PHARMA SHARES
|
|
| | | |
| 2007 Release |
|
| December 27, 2007 |
|
U.S. District Court Decision about Eisai's Legal Action over Aricept ODT® ANDA Filing
|
|
| December 25, 2007 |
|
Eisai Introduces New Aricept® Dose Formulations for Treatment of Severe Alzheimer's Disease in Japan
|
|
| December 18, 2007 |
|
Eisai Enters into In-licensing Agreement with Minophagen Pharmaceutical for Liver Disease/Allergic Disease Agents Stronger Neo-Minophagen® C and Glycyron® Tablets for Allergic Disease
|
|
| December 10, 2007 |
|
Eisai to Acquire MGI PHARMA, INC.
|
|
| December 6, 2007 |
|
Eisai Celebrates Ground-Breaking Ceremony For New Manufacturing and Research Base in India
|
|
| December 4, 2007 |
|
Eisai and BioArctic Neuroscience Enter Exclusive Licensing Agreement with Novel Antibody Treatment for Alzheimer's Disease
|
|
| November 29, 2007 |
|
Eisai Submits NDA Application of KES524 for Obesity Management in Japan
|
|
| October 30, 2007 |
|
Eisai Announces Change in Regulatory Submission Strategy of E2007 for Parkinson's Disease
|
|
| September 28, 2007 |
|
Eisai Announces Establishment of New Pharmaceutical Marketing Subsidiary in Belgium
|
|
| September 28, 2007 |
|
Kissei and Eisai sign a license agreement to develop and commercialize Glufast®, a rapid-acting insulin secretagogue in China
|
|
| September 25, 2007 |
|
Abbott and Eisai submit application for adalimumab, the only fully human monoclonal anti-TNF antibody, to treat psoriasis
|
|
| September 5, 2007 |
|
Eisai Inc. Enters Exclusive Agreement with Salix Pharmaceuticals, Ltd. to Co-promote “COLAZAL®” for the Treatment of Ulcerative Colitis in the U.S. Market
|
|
| August 24, 2007 |
|
Approval of an additional dosage and administration for secondary eradication of Helicobacter pylori for proton pump inhibitors in Japan
|
|
| August 23, 2007 |
|
Aricept® Receives Approval for Additional Efficacy and Dosage For Treatment of Severe Alzheimer's Disease in Japan
|
|
| August 23, 2007 |
|
Sanko Junyaku and Eisai to Co-promote “Picolumi® ucOC”, Diagnostic Agent Introduced by Sanko Junyaku
New Diagnostic Agent Helps Physicians Make Prescribing Choice for Vitamin K2 Medication Therapy for Osteoporosis Patients
|
|
| August 11, 2007 |
|
UK High Court Ordered NICE To Amend A Guidance for Alzheimer's Disease
|
|
| August 10, 2007 |
|
UK High Court Ruled NICE Guidance for Alzheimer's Disease Discriminatory
|
|
| July 31, 2007 |
|
Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders
|
|
| July 27, 2007 |
|
Eisai Co-promotes “PyloriTek® Test Kit”, H. Pylori Infection Diagnostic Kit Launched by Sanko Junyaku
|
|
| July 27, 2007 |
|
Eisai Enters into In-licensing Agreement with Sepracor for Eszopiclone Insomnia Treatment
|
|
| July 17, 2007 |
|
New Individually-Wrapped Tablets Introduced to Selbelle®:
Stomach Medication that Protects Gastric Mucosa from Stomach Acid Now Available in Easy-to-Carry Package
|
|
| July 11, 2007 |
|
Eisai Launches “Nitorol® Injection 5 mg Syringe” and “Nitorol® Continuous Intravenous Infusion 25 mg Syringe”, First Nitric Acid Syringe Formulations Approved in Japan
|
|
| July 9, 2007 |
|
Notice on Details of Stock Options (New Share Acquisition Rights) to be Allocated
|
|
| June 26, 2007 |
|
Tambocor® (Antiarrthymic Treatment) Received Approval for Paroxysmal Atrial Fibrillation/Flutter
|
|
| June 22, 2007 |
|
Notice on Allocation of Stock Options (Stock Acquisition Rights)
|
|
| June 16, 2007 |
|
Inovelon® launched in Germany
|
|
| June 15, 2007 |
|
A ONCE-WEEKLY ANTIOSTEOPOROTIC AGENT “ACTONEL® 17.5 mg TABLETS” IS LAUNCHED.
|
|
| June 12, 2007 |
|
Kissei and Eisai sign a license agreement to develop and commercialize Glufast®, a rapid-acting insulin secretagogue in 10 ASEAN countries
|
|
| May 15, 2007 |
|
Eisai Signs Exclusive Agreement to Commercialize NeuroBloc® for Europe
|
|
| May 15, 2007 |
|
Eisai Submits Application for Gastroprokinetic Agent Gasmotin® in Thailand
|
|
| May 15, 2007 |
|
Notice on New Stock Issuance in the Form of Stock Options
|
|
| May 15, 2007 |
|
Basic Principle and Policies concerning Reduction of Minimum Trading Lots for Shares
|
|
| May 12, 2007 |
|
EISAI OBTAINS FAVORABLE RULING IN ACIPHEX® PATENT INFRINGEMENT LAWSUIT AGAINST TEVA PHARMACEUTICALS AND DR. REDDY'S LABORATORIES
|
|
| May 7, 2007 |
|
Eisai Introduces “Chocola BB® Light 2” Vitamin B2 Drink
A New Drink with Enhanced Formula and Reduced Calories
|
|
| May 7, 2007 |
|
FDA Approves FRAGMIN®, an Injectable Anti-Clotting Agent, for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
|
|
| April 26, 2007 |
|
Eisai Announces Complete Subsidiarization of Sanko Junyaku
|
|
| April 18, 2007 |
|
A ONCE-WEEKLY FORMULATION OF RISEDRONATE SODIUM HYDRATE, AN ANTIOSTEOPOROTIC AGENT, WAS APPROVED.
|
|
| April 17, 2007 |
|
Eisai Announces Completion of Acquisition of Morphotek
|
|
| April 13, 2007 |
|
Eisai Withdraw Application for Additional Indication of Aricept® for Treatment of Severe Alzheimer's Disease in Europe
|
|
| March 26, 2007 |
|
Asahi Kasei Pharma Corporation and Eisai Co., Ltd.
Signed License Agreement for Vasodilator Eril® in Korea
|
|
| March 22, 2007 |
|
EISAI TO ACQUIRE MORPHOTEK
Eisai's Dramatic Leap towards Biologic Therapeutics Evidenced by the Acquisition
|
|
| March 5, 2007 |
|
Eisai Establishes New Manufacturing Subsidiary in United Kingdom
|
|
| March 1, 2007 |
|
Eisai and Abbott Announce Amendment to Agreement for the Co-promotion of Rheumatoid Arthritis Drug HUMIRA® in Taiwan and Korea
|
|
| February 2, 2007 |
|
Notice Regarding Revision of Year End Dividend Forecast For Fiscal Year Period (95th Company Fiscal Period) Ending March 2007
|
|
| January 30, 2007 |
|
Proton Pump Inhibitor Pariet® Tablets 10mg Receives Approval in Japan for Helicobacter Pylori Eradication
|
|
| January 22, 2007 |
|
Inovelon® recieves Marketing Authorization Approval from European Commission
|
|
| | | |
|
|
|
